Concepedia

Publication | Closed Access

Thalidomide treatment of resistant or relapsed multiple myeloma patients.

85

Citations

0

References

2001

Year

Marek Hus, Anna Dmoszyńska, Maria Soroka‐Wojtaszko, Dariusz Jawniak, Wojciech Legieć, H Ciepnuch, Andrzej Hellmann, Teresa Wolska-Smoleń, A B Skotnicki, Joanna Mańko
PubMed

Abstract

In responding patients the earliest response was observed after 4 weeks of treatment and the latest after 12 weeks of treatment. Our results, obtained during a long observation period, show that thalidomide is an effective drug, with an acceptable degree of toxicity, in patients with refractory multiple myeloma.